Vivek Ramaswamy
 | A major contributor to this article appears to have a close connection with its subject. (March 2017) |
Vivek Ramaswamy | |
|---|---|
| Born | August 9, 1985 Cincinnati, Ohio, U.S. |
| Education | Harvard University Yale Law School |
| Title | CEO & Founder of Roivant Sciences Founder of Axovant Sciences |
Vivek Ramaswamy (born August 9, 1985) is an American entrepreneur in the biotechnology sector. He is the founder and CEO of the pharmaceutical company Roivant Sciences. He is also the founder of Axovant Sciences, a clinical-stage pharmaceutical company focusing on treatments for dementia.
Early life
Ramaswamy was born on August 9, 1985 in Cincinnati, Ohio.[1] He is the eldest son in his family. His father worked at General Electric and his mother, Geetha Ramaswamy, is a geriatric psychiatrist.[2]
Ramaswamy attended Harvard College where he graduated summa cum laude with an A.B in biology. He also holds a J.D. from Yale Law School, which The Paul & Daisy Soros Fellowships for New Americans supported. He graduated valedictorian from his high school in Cincinnati where he was a nationally ranked junior tennis player.[3]
Career
Ramaswamy was an investor in the biotechnology sector. In 2007, he co-founded and served as President of Campus Venture Network, a technology company that was acquired in 2009 by the Ewing Marion Kauffman Foundation. Ramaswamy worked at QVT Financial from 2007 to 2014, where he was a partner and co-managed the firm’s biotech portfolio.[4]
Ramaswamy is the founder and CEO of the pharmaceutical company Roivant Sciences. He is also the founder of Axovant Sciences, a clinical-stage pharmaceutical company focusing on treatments for dementia. The initial public offering for Axovant in 2015 raised $360 million, making it the largest biotech IPO in U.S. history.
Ramaswamy serves on the Board of Directors of Myovant Sciences, a subsidiary of Roivant Sciences focused on the treatment of women’s health diseases and other endocrine-related disorders. Myovant, formed in April 2016, raised $218 million in its initial public offering, the largest biotech IPO of 2016.[5]
Ramaswamy also serves as Chairman of the Board of Directors of Arbutus Biopharma Corporation, a company focused on developing a cure for patients with chronic hepatitis B through the use of combination therapies.[6]
Personal life
Ramaswamy currently resides in Manhattan with his wife. As of April 2017, he is worth an estimated $600 million.[7]
References
- ^ "Vivek Ramaswamy Birth Records".
- ^ "America's Richest Entrepreneurs Under 40: Vivek Ramaswamy".
- ^ "The 30-Year-Old CEO Conjuring Drug Companies From Thin Air".
- ^ "The 29 Year Old Behind The Giant Biotech IPO That Rose By 90% Speaks".
- ^ "Biggest Biotech IPO Of 2016 Is Launched By 31 Year Old".
- ^ "Arbutus Biopharma Board of Directors".
- ^ Kroll, Luisa (April 4, 2017). "America's Richest Entrepreneurs Under 40 2016". Forbes. Retrieved April 5, 2017.